Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

Takeda denies $12bn Nycomed takeover reports

May 13, 2011 Research and Development, Sales and Marketing Nycomed, Takeda

Japan’s biggest pharma firm Takeda has denied reports it is negotiating a billion dollar deal to acquire Swiss speciality firm …
News
European Parliament

EMA under fire from European Parliament

May 13, 2011 Medical Communications, Research and Development, Sales and Marketing EMA, European Parliament, MEPs

The EMA has been hit by a barrage of criticism from the European Parliament over conflicts of interest and the …
News

Government wrong to push for Avastin in eye disease, says charity

May 12, 2011 Research and Development, Sales and Marketing Lucentis, RNIB, avastin, wet AMD

The UK government’s pursuit of Avastin for use in ophthalmology is bad for patients, says the Royal National Institute of …
News
Roche

Roche aims for wholly personalised skin cancer drug

May 12, 2011 Sales and Marketing Roche, personalised medicine, skin cancer, vemurafenib

Roche has submitted its key skin cancer drug vemurafenib to European and American regulators for approval. Vemurafenib (formerly RG7204) has …
News

PCTs increasingly ‘red list’ drugs to cut costs

May 12, 2011 Sales and Marketing GP prescribing deicisions, GPs, PCTs, prescribing

GPs are being asked not to prescribe NICE-approved drugs in order to cut costs. In the last year more than …
Feature
Novo Nordisk headquarters

New product can overtake Lantus, says Novo leader

May 11, 2011 Sales and Marketing Novo Nordisk, degludec, diabetes, insulin

Novo Nordisk’s new insulin product can eclipse Sanofi’s Lantus within just a few years of its launch, according to Novo’s …
News

Verdict on AMT’s gene therapy expected soon

May 11, 2011 Research and Development, Sales and Marketing AMT, Amsterdam Molecular Therapeutics, gene therapy, genes

Amsterdam Molecular Therapeutics says it will shortly receive the regulatory verdict on its gene therapy Glybera. Glybera (alipogene tiparvovec) is …
News
Blog footer

Digital Pharma: NICE puts guidance into online pathways

May 11, 2011 Sales and Marketing Digital Pharma blog, NICE

NICE has launched a new online tool that groups its guidance into user-friendly flowcharts to show care pathways. NICE Pathways …
News
Bayer

FDA fast-tracks Bayer’s GIST drug regorafenib

May 10, 2011 Sales and Marketing Bayer, GIST, regorafenib

The assessment of Bayer HealthCare’s investigational drug regorafenib is to be fast-tracked by US authorities for the treatment of stomach …
News

French pharma firm denies drug risk cover up

May 10, 2011 Sales and Marketing Mediator, Servier, drug safety

France’s second biggest pharma firm Servier has denied allegations it concealed risks associated with its diabetes drug Mediator (benfluorex). Research …
News
Sanofi's new logo

Sanofi name change sees Aventis dropped

May 9, 2011 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, Sanofi-Aventis

Sanofi-Aventis will now just be known as Sanofi after the French pharma company’s shareholders agreed to change its name. Following …
News
Pfizer

Pfizer’s Revatio extends Europe PAH licence

May 9, 2011 Sales and Marketing PAH, Pfizer, pulmonary arterial hypertension, revatio

Pfizer’s Revatio has been approved by European regulators for the treatment of pulmonary arterial hypertension (PAH) in children.The European Commission has …
News
Sanofi headquarters

Sanofi abandons $375m oral diabetes deal

May 9, 2011 Sales and Marketing Metabolex, Sanofi, diabetes

Sanofi has terminated its $375 million deal with US biotech Metabolex to develop a novel oral anti-diabetic treatment. The French …
News
Pfizer

Pfizer signs Chinese commercial collaboration

May 9, 2011 Sales and Marketing China, Pfizer, Shanghai Pharmaceutical Co

US giant Pfizer looks set to collaborate with Shanghai Pharmaceutical Co. on business opportunities in China. The potential partnership is …
News

Pay-for-delay deals up 60% in US

May 6, 2011 Sales and Marketing FTC, generics

Deals to delay generic drugs from coming onto the US market have more than doubled. The Federal Trade Commission’s staff …
News
The Gateway to Local Adoption Series

Latest content

IsomAb appoints Philip Brainin as CEO

March 19, 2026

Naobios partners with SGS to manufacture RSV challenge agent

March 19, 2026

Qlaris Bio appoints Fred Guerard as President and CEO

March 18, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

March 18, 2026

AEON Biopharma appoints John Bencich as CFO

March 17, 2026